BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO

BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO

Библиографические подробности
Главные авторы:	Hammitzsch, A, de Wit, J, Ridley, A, Al-Mossawi, M, Knapp, S, Bowness, P
Формат:	Journal article
Опубликовано:	2014

Схожие документы

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
по: Hammitzsch, A, и др.
Опубликовано: (2015)

Elevated type-17 cytokines are present in Axial Spondyloarthritis stool
по: Brough, I, и др.
Опубликовано: (2024)

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
по: Hammitzsch, A, и др.
Опубликовано: (2018)

SUPPRESSION OF IN-VITRO TYPE-17 RESPONSES IN SPA PATIENTS USING SMALL MOLECULE ROR-gamma T INHIBITORS
по: De Wit, J, и др.
Опубликовано: (2014)

The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis
по: Al-Mossawi, M, и др.
Опубликовано: (2013)

The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis.
по: Al-Mossawi, M, и др.
Опубликовано: (2013)

miR-10b-5p is a novel Th17 regulator present in Th17 cells from Ankylosing Spondylitis
по: Chen, L, и др.
Опубликовано: (2017)

Novel therapeutic targets in axial spondyloarthritis
по: Worth, C, и др.
Опубликовано: (2018)

Pathogenic immune responses in Spondyloarthritis
по: Al-Mossawi, M
Опубликовано: (2016)

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis.
по: Chen, L, и др.
Опубликовано: (2015)

CHARACTERIZING TYPE 17 IMMUNE RESPONSES IN ANKYLOSING SPONDYLITIS
по: Al-Mossawi, H, и др.
Опубликовано: (2013)

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates
по: Simone, D, и др.
Опубликовано: (2021)

Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates
по: Simone, D, и др.
Опубликовано: (2021)

T cell phenotype and function in Spondyloarthritis
по: Ridley, AL
Опубликовано: (2013)

Unique trancriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis
по: Al-Mossawi, M, и др.
Опубликовано: (2017)

HLA-B27 and KIR3DL2 Interactions Promote The Differentiation and Survival Of Proinflammatory T Cells In Spondyloarthritis
по: Ridley, A, и др.
Опубликовано: (2013)

Discovery of BET bromodomain inhibitors and their role in target validation
по: Mueller, S, и др.
Опубликовано: (2014)

RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.
по: de Wit, J, и др.
Опубликовано: (2015)

Small-molecule bromodomain inhibitors for cancer therapy
по: Qi, J, и др.
Опубликовано: (2010)

The role of HLA-B27 in spondyloarthritis.
по: Allen, R, и др.
Опубликовано: (1999)

Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
по: Ferguson, F, и др.
Опубликовано: (2013)

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
по: Ciceri, P, и др.
Опубликовано: (2014)

Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
по: Popp, T, и др.
Опубликовано: (2016)

Developing small molecule inhibitors of the CREBBP bromodomain-histone interaction
по: Rooney, T, и др.
Опубликовано: (2012)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
по: Philpott, M, и др.
Опубликовано: (2011)

Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery.
по: Philpott, M, и др.
Опубликовано: (2011)

The KIRs of HLA-B27: the role of HLA-B27 KIR interactions in infection and spondyloarthritis
по: Wong-Baeza, I, и др.
Опубликовано: (2011)

Developing inhibitors of bromodomain-histone interactions
по: Hewings, D
Опубликовано: (2014)

Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
по: Ahmed, S, и др.
Опубликовано: (2024)

Effect of BET missense mutations on bromodomain function, inhibitor binding and stability
по: Lori, L, и др.
Опубликовано: (2016)

The bromodomain interaction module.
по: Filippakopoulos, P, и др.
Опубликовано: (2012)

The bromodomain interaction module
по: Filippakopoulos, P, и др.
Опубликовано: (2012)

Activation-induced killer cell immunoglobulin-like receptor 3DL2 binding to HLA-B27 licenses pathogenic T cell differentiation in spondyloarthritis
по: Ridley, A, и др.
Опубликовано: (2016)

Corrigendum: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
по: Ciceri, P, и др.
Опубликовано: (2014)

Bromodomains as therapeutic targets.
по: Muller, S, и др.
Опубликовано: (2011)

Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.
по: Catherine, S, и др.
Опубликовано: (2005)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
по: Filippakopoulos, P, и др.
Опубликовано: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
по: Filippakopoulos, P, и др.
Опубликовано: (2012)

PHENOTYPIC CHARACTERIZATION OF NATURAL KILLER CELLS AND RECEPTORS IN SPONDYLOARTHRITIS
по: Chan, A, и др.
Опубликовано: (2004)

THE ROLE OF HLA-B27 KIR3DL2 INTERACTIONS IN THE PATHOGENESIS OF SPONDYLOARTHRITIS
по: Kollnberger, S, и др.
Опубликовано: (2012)